Doing the ‘Patent Dance:’ Untangling biosimilar litigation for physicians

Despite their much-touted potential to drastically lower the cost of pricey biologics and improve care for patients across a spectrum of diseases, biosimilars have been slow to take root across the country, particularly in comparison with Europe.Although 26 biosimilars have been approved by the FDA since the Biologics Price Competition and Innovation Act (BPCIA) was signed into law as part of the Affordable Care Act in 2010, just 11 have actually made their way to the U.S. marketplace. Part of the reason for this slow uptake has been ongoing litigation. In one example, a U.S. District CourtRead More

Share on facebook
Share on twitter
Share on linkedin